Annual report
4272.TEDINET S100ODM3
Period2021-04-01 → 2022-03-31
Filed2022-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 153
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥184.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥173.4bn | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥175.1bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥172.6bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥167.9bn | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥21.1bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | ¥15.2bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | ¥23.2bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥16.5bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥18.0bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥21.6bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥22.5bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥23.7bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥17.5bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥17.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥12.6bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥12.8bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.9bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥15.5bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥17.2bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | ¥12.6bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥315.5bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥294.5bn | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥278.5bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥293.6bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥285.6bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥69.0bn | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥66.3bn | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥246.4bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥228.3bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥210.0bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥229.0bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥220.6bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥38.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥33.3bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥53.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥47.5bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.7bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥52.7bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥50.5bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥23.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥24.4bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥27.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥26.8bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥20.1bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥10.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥17.6bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥17.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥17.7bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥16.2bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥11.1bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥8.4bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥13.9bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.2bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥101.7 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.62 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.25 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥85.77 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥89.45 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥101.65 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥73.61 | 2020-04-01 → 2021-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥74.23 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥85.75 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥89.44 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,459.06 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,332.06 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,225.71 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,247.75 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,203.23 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 77.8% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.2% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 75.2% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.6% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.9% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 7.3% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.8% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.0% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.0% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.7% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 5,703 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 5,664 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 5,847 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 5,814 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 5,684 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥124.0bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥115.6bn | 2020-04-01 → 2021-03-31 | Standalone | Net sales |
| Revenue | ¥106.6bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥103.4bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥102.2bn | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥11.6bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥9.4bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥16.1bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥13.5bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥13.5bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥13.0bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.2bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥16.5bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥25.8bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥12.6bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥22.6bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | ¥10.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥10.4bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥12.7bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥236.4bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥230.8bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥215.5bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥208.0bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥203.6bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥51.6bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥50.4bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥184.8bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥180.4bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥160.8bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥161.7bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥156.8bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥11.6bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥11.9bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥74.63 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥132.38 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥62.01 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.19 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.09 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥40 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,098.36 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,056.38 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥941.59 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥934.13 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥905.43 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 78.2% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 78.2% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.6% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.8% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.0% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.9% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 13.3% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.6% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.3% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 170,503,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 177,503,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 177,503,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 182,503,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 182,503,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 2,398 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 2,401 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 2,069 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 2,079 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 1,845 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 102
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2021-04-01 → 2022-03-31 | ¥851m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-04-01 → 2022-03-31 | ¥701m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 122 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥9.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥9.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥105m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥19.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | ¥1.8bn |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥356m |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥527m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥249m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥249m |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥55.7bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥7.2bn |
| Functional Chemicalsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥3.6bn |
| Functional Chemicalsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥5.0bn |
| Functional Chemicalsreportable segment | employees | at 2022-03-31 | 2092 pure |
| Functional Chemicalsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥77.3bn |
| Functional Chemicalsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥77.2bn |
| Functional Chemicalsreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥143m |
| Functional Chemicalsreportable segment | segment assets | at 2022-03-31 | ¥104.7bn |
| Functional Chemicalsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥11.5bn |
| Pharmaceuticalsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥1.8bn |
| Pharmaceuticalsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥1.9bn |
| Pharmaceuticalsreportable segment | employees | at 2022-03-31 | 828 pure |
| Pharmaceuticalsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥52.1bn |
| Pharmaceuticalsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥52.1bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥0 |
| Pharmaceuticalsreportable segment | segment assets | at 2022-03-31 | ¥58.1bn |
| Pharmaceuticalsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥8.6bn |
| Safety Systemsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥2.5bn |
| Safety Systemsreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥5.5bn |
| Safety Systemsreportable segment | employees | at 2022-03-31 | 2444 pure |
| Safety Systemsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥46.1bn |
| Safety Systemsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥46.1bn |
| Safety Systemsreportable segment | segment assets | at 2022-03-31 | ¥77.0bn |
| Safety Systemsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥6.3bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥7.9bn |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥12.3bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥175.5bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥175.3bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥144m |
| —segment total | segment assets | at 2022-03-31 | ¥239.8bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥26.5bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥8.7bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥13.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥185.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥184.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥249m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥259.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥28.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2020-04-01 → 2021-03-31 | ¥611m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2020-04-01 → 2021-03-31 | ¥691m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2020-04-01 → 2021-03-31 | ¥8.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2020-04-01 → 2021-03-31 | ¥8.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥97m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2021-03-31 | ¥19.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2020-04-01 → 2021-03-31 | ¥1.8bn |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥426m |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥560m |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥235m |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥235m |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥57.4bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥6.8bn |
| Functional Chemicalsreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥10.9bn |
| Functional Chemicalsreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥4.8bn |
| Functional Chemicalsreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥72.6bn |
| Functional Chemicalsreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥72.5bn |
| Functional Chemicalsreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥137m |
| Functional Chemicalsreportable segment | segment assets | at 2021-03-31 | ¥94.2bn |
| Functional Chemicalsreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥7.3bn |
| Pharmaceuticalsreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥1.5bn |
| Pharmaceuticalsreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥1.8bn |
| Pharmaceuticalsreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥50.4bn |
| Pharmaceuticalsreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥50.4bn |
| Pharmaceuticalsreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥0 |
| Pharmaceuticalsreportable segment | segment assets | at 2021-03-31 | ¥54.3bn |
| Pharmaceuticalsreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥7.4bn |
| Safety Systemsreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥3.2bn |
| Safety Systemsreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥4.9bn |
| Safety Systemsreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥42.0bn |
| Safety Systemsreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥42.0bn |
| Safety Systemsreportable segment | segment assets | at 2021-03-31 | ¥68.9bn |
| Safety Systemsreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥5.4bn |
| —segment total | capex | 2020-04-01 → 2021-03-31 | ¥15.6bn |
| —segment total | depreciation | 2020-04-01 → 2021-03-31 | ¥11.6bn |
| —segment total | revenue | 2020-04-01 → 2021-03-31 | ¥165.0bn |
| —segment total | revenue external | 2020-04-01 → 2021-03-31 | ¥164.9bn |
| —segment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥137m |
| —segment total | segment assets | at 2021-03-31 | ¥217.4bn |
| —segment total | segment profit | 2020-04-01 → 2021-03-31 | ¥20.2bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2020-04-01 → 2021-03-31 | ¥16.2bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2020-04-01 → 2021-03-31 | ¥12.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2020-04-01 → 2021-03-31 | ¥173.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2020-04-01 → 2021-03-31 | ¥173.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥235m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2021-03-31 | ¥237.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2020-04-01 → 2021-03-31 | ¥22.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 122 pure |
| Functional Chemicalsreportable segment | employees | at 2022-03-31 | 950 pure |
| Pharmaceuticalsreportable segment | employees | at 2022-03-31 | 777 pure |
| Safety Systemsreportable segment | employees | at 2022-03-31 | 334 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,076
| Item | Context | Value | Unit |
|---|---|---|---|
| Total assets (5-year summary) | CurrentYearInstant | 315459000000 | JPY |
| Net assets per share (5-year summary) | Prior4YearInstant | 1203.23 | |
| Net assets per share (5-year summary) | Prior3YearInstant | 1247.75 | |
| Net assets per share (5-year summary) | Prior2YearInstant | 1225.71 | |
| Net assets per share (5-year summary) | Prior1YearInstant | 1332.06 | |
| Net assets per share (5-year summary) | CurrentYearInstant | 1459.06 | |
| Basic earnings loss per share (5-year summary) | Prior4YearDuration | 89.45 | |
| Basic earnings loss per share (5-year summary) | Prior3YearDuration | 85.77 | |
| Basic earnings loss per share (5-year summary) | Prior2YearDuration | 74.25 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 73.62 | |
| Basic earnings loss per share (5-year summary) | CurrentYearDuration | 101.70 | |
| Diluted earnings per share (5-year summary) | Prior4YearDuration | 89.44 | |
| Diluted earnings per share (5-year summary) | Prior3YearDuration | 85.75 | |
| Diluted earnings per share (5-year summary) | Prior2YearDuration | 74.23 | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 73.61 | |
| Diluted earnings per share (5-year summary) | CurrentYearDuration | 101.65 | |
| Equity to asset ratio (5-year summary) | Prior4YearInstant | 0.729 | |
| Equity to asset ratio (5-year summary) | Prior3YearInstant | 0.736 | |
| Equity to asset ratio (5-year summary) | Prior2YearInstant | 0.752 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.772 | |
| Equity to asset ratio (5-year summary) | CurrentYearInstant | 0.778 | |
| Rate of return on equity (5-year summary) | Prior4YearDuration | 0.077 | |
| Rate of return on equity (5-year summary) | Prior3YearDuration | 0.070 | |
| Rate of return on equity (5-year summary) | Prior2YearDuration | 0.060 | |
| Rate of return on equity (5-year summary) | Prior1YearDuration | 0.058 | |
| Rate of return on equity (5-year summary) | CurrentYearDuration | 0.073 | |
| Price earnings ratio (5-year summary) | Prior4YearDuration | 14.6 | |
| Price earnings ratio (5-year summary) | Prior3YearDuration | 15.2 | |
| Price earnings ratio (5-year summary) | Prior2YearDuration | 13.4 | |
| Price earnings ratio (5-year summary) | Prior1YearDuration | 14.5 | |
| Price earnings ratio (5-year summary) | CurrentYearDuration | 11.4 | |
| Net cash provided by used in operating activities (5-year summary) | Prior4YearDuration | 20121000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior3YearDuration | 26803000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior2YearDuration | 27281000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | Prior1YearDuration | 24408000000 | JPY |
| Net cash provided by used in operating activities (5-year summary) | CurrentYearDuration | 23141000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior4YearDuration | -16171000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior3YearDuration | -17694000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior2YearDuration | -17543000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration | -17606000000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYearDuration | -10641000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior4YearDuration | -6241000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior3YearDuration | -6437000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior2YearDuration | -13894000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration | -8402000000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYearDuration | -11090000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior4YearInstant | 50532000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior3YearInstant | 52697000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior2YearInstant | 46663000000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant | 47483000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |